key: cord-1041001-0u61qgs6
authors: Turecek, Peter L.; Peck, Rachel C.; Rangarajan, Savita; Reilly-Stitt, Christopher; Laffan, Michael A.; Kazmi, Rashid; James, Izabela; Dushianthan, Ahilanandan; Schrenk, Gerald; Gritsch, Herbert; Ewenstein, Bruce M.; Mellgard, Bjorn; Erdlenbruch, Wolfhard; Jain, Nisha; Binder, Nikolaus B.; Mumford, Andrew D.
title: Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19
date: 2021-02-18
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.02.012
sha: e4635b13b7eb352a0a01aea393c59e89eba8ca08
doc_id: 1041001
cord_uid: 0u61qgs6

Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis remain unconfirmed. In a cross-sectional cohort of 36 severe COVID-19 patients, we show that markedly increased plasma von Willebrand factor (VWF) levels were accompanied by a partial reduction in the VWF regulatory protease ADAMTS13. In all patients we find this VWF/ADAMTS13 imbalance to be associated with persistence of ultra-high-molecular-weight (UHMW) VWF multimers that are highly thrombogenic in some disease settings. Incubation of plasma samples from patients with severe COVID-19 with recombinant ADAMTS13 (rADAMTS13) substantially reduced the abnormally high VWF activity, reduced overall multimer size and depleted UHMW VWF multimers in a time and concentration dependent manner. Our data implicate disruption of normal VWF/ADAMTS13 homeostasis in the pathogenesis of severe COVID-19 and indicate that this can be reversed ex vivo by correction of low plasma ADAMTS13 levels. These findings suggest a potential therapeutic role for rADAMTS13 in helping restore haemostatic balance in COVID-19 patients.

Early experience from the COVID-19 pandemic has shown that in susceptible individuals, SARS-CoV-2 infection results in a thrombotic coagulopathy that is a frequent cause of adverse clinical outcomes [1, 2] . It is proposed that coagulopathy is primarily the consequence of vascular endothelial dysfunction driven by an exaggerated host inflammatory response to SARS-CoV-2 or from the direct effect of viral replication within endothelial cells [2, 3] . In severe COVID-19, this results in the deposition of platelet and fibrin rich thrombi in small pulmonary blood vessels [4] and sometimes thrombosis in large peripheral veins or arteries [5, 6] .

In line with this model of pathogenesis, plasma markers of endothelial activation are consistently elevated in severe COVID-19 and correlate with adverse outcomes [2] .

These include von Willebrand factor (VWF), which is a critical mediator of adhesive interactions between circulating platelets and the damaged vessel wall in the normal haemostatic response [7] . VWF is synthesised by endothelial cells, stored in Weibel-Palade bodies and released as ultra-high molecular weight (UHMW) multimers.

These UHMW multimers are potent mediators of platelets adhesion to other platelets and to subendothelial structures exposed upon vessel damage. However, under normal circumstances UHMW VWF multimers are rapidly cleaved to smaller sized multimers with lower thrombogenic potential by the plasma protease ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13) [8] .

Disorders such as thrombotic thrombocytopenic purpura (TTP) in which there is severe autoimmune-mediated or hereditary deficiency of ADAMTS13 activity result in increased levels of VWF and in particular, the persistence of circulating UHMW VWF multimers. This manifests as the formation of abnormal platelet rich thrombi in ELISA (Technoclone) using immobilized recombinant nuclear SARS-CoV-2 protein.

In both ELISAs, the captured patient antibodies are detected using an anti-human IgG HRP labelled polyclonal antibody and quantified using SARS-CoV-2 positive serum standardized against a specific monoclonal antibody for RBD (CR3022).

Blood samples collected into 3.2 % Trisodium citrate were centrifuged at 2400g for 10 minutes to yield plasma aliquots which were stored at -80 • C or in temperature monitored dry ice until analysis. The prothrombin time, activated partial thromboplastin time, Clauss fibrinogen and D dimer were measured using a CS-2500 series analyser (Sysmex Corp. Kobe, Japan) using Siemens Healthcare reagents (Marburg, Germany). The Factor VIII activity was determined using a onestage activity assay with Actin FS activator and FVIII deficient plasma from Siemens Healthcare. 

Three complementary assays were used to determine ADAMTS13 levels, all obtained from Technoclone (Vienna, Austria). TECHNOZYM ADAMTS13 Activity ELISA is a chromogenic assay in which the endpoint is proteolysis of the substrate GST-VWF73 [21, 22] . TECHNOFLOUR ADAMTS13 Activity is an automated assay for the Ceveron s100 instrument which uses a FRET substrate based on the VWF73 peptide [23] . TECHNOZYM ADAMTS13 Antigen ELISA is a sandwich ELISA employing anti-ADAMTS 13 antigen directed to the CUB domain and secondary HRP labelled anti-ADAMTS13 polyclonal antibodies [24] . All ADAMTS13 parameters were calculated using assay specific reference plasma calibrated against the WHO standard. The COVID-19 patient samples were analysed alongside a control plasma sample from a 48 year old male with autoimmune TTP (known ADAMTS13 activity <0.01 IU/mL) and a normal pooled plasma sample (ADAMTS13 activity 0.9 -1.0 IU/mL; Precision BioLogic, Dartmouth, NS, Canada).

Analysis of VWF multimeric composition was initially performed using home cast low-resolution 1 % and high-resolution 2.5 % SDS agarose gels (SeaKem, Lonza, Basel, Switzerland) which are optimized to separate VWF multimers >20 MDa which are larger than those present in normal human plasma. In order to minimise infectivity before open electrophoresis using the home cast gels, the plasma samples underwent heat inactivation for 1 hour at 60°C. The samples were then diluted so that 1 IU VWF:Ag/mL was applied to each electrophoresis gel lane to assist direct visual comparison between lanes and quantitative densitometric scanning. The findings from the home cast gel electrophoresis were validated using a semiautomated electrophoresis gel method using the HYDRAGEL von WILLEBRAND MULTIMERS kit and a HYDRASYS 2 SCAN instrument (Sebia, Lisses, France). This method separates VWF multimers in the high to ultra-large range less well than the home cast 1 % agarose gels but shows better reproducibility between gels.

J o u r n a l P r e -p r o o f rADAMTS13 Manufacture and characterisation of purified recombinant human ADAMTS13 (rADAMTS13, Takeda, Vienna, Austria) from a Chinese hamster ovary cell line has been described previously [26] [27] [28] . The rADAMTS13 product used in our investigation is the same as the investigational drug candidate identified as TAK-755, SHP655, or BAX 930 in clinical trials for hereditary thrombotic thrombocytopenic purpura (ClinicalTrials.gov Identifier: NCT02216084) and for sickle cell disease (ClinicalTrials.gov Identifier: NCT03997760).

Degradation of VWF with rADAMTS13 was performed under conditions where VWF is partially denatured to make the cleavage motif accessible for proteolysis. The rADAMTS13 was pre-diluted to 10 and 100 IU/mL FRETS-VWF73 activity (final concentrations between 0.5 and 10 IU/mL) and activated with BaCl 2 in the presence of 5 mM Tris and 1.5 M urea, pH 8.0, at 37°C for 30 minutes. Activated rADAMTS13 was mixed 1+9 with patient plasma samples and further incubated at 37°C for 2 and 5 hours before proteolysis was stopped by the addition of Na 2 SO 4 (8.25 mM final concentration). In control experiments to measure the effect of the endogenous ADAMTS13, the patient samples were mixed with buffer instead of rADAMTS13.

Samples were centrifuged at 2500 x g for 5 minutes and the VWF in the supernatants was analysed using the VWF:CB assay and by quantitative densitometry of semi-automated electrophoresis gels performed with the Sebia Phoresis rel. 9.2.0 software to calculate relative increase of VWF dimer levels relative to the total quantity of VWF determined from the areas under the J o u r n a l P r e -p r o o f densitometry curves. UHMW VWF multimers were quantified from the home case gels as described above.

Descriptive statistics and Pearson correlation analysis were performed to determine correlations (r) between ADAMTS13 and VWF levels measured with the different test methods. In order to investigate the extent of degradation of VWF by rADAMTS13 in the ex vivo VWF cleavage experiments, paired t-tests were used to compare VWF:CB assay data (10 samples) and relative VWF dimer content from semiautomated electrophoresis gels (8 samples) baseline and after 5 hours of incubation with 1 IU/mL rADAMTS13. All the statistical analyses were performed using Minitab version 18.1. [29] . The clinical and core laboratory characteristics of the patients are reported in Table 1 .

All of the COVID-19 patients had plasma VWF protein levels (VWF:Ag) above the upper limit of our laboratory reference interval derived from healthy volunteer plasma samples. In one third of cases, VWF levels were more than five-fold higher than average normal levels and in two cases were more than ten-fold higher ( Figure 1 ).

There was a corresponding dramatic increase in plasma VWF activity determined using both the VWF:RCo and VWF:CB assays.

By contrast, levels of ADAMTS13 protein (ADAMTS antigen) and activity determined both by the ELISA and FRETS assays were in most patients reduced to between 30 and 70 percent of average normal levels ( Figure 1 ). No COVID-19 patients displayed ADAMTS13 activity levels less than 20 percent of average normal levels, distinguishing these from the autoimmune TTP control in which ADAMTS13 activity was undetectable by any of the assays. VWF levels determined using activity and antigen tests showed a strong to moderate negative correlation with ADAMTS13 levels ( Figure 2 ).

Visual inspection of the immunostained low-resolution agarose gels showed that UHMW VWF multimers were present in all 36 of the COVID-19 patients. As expected, UHMW VWF multimers were also present in the control sample from a patient with autoimmune TTP and were absent in all of the control samples from healthy volunteers (Figure 3 ). The additional UHMW VWF multimers resulted in an increase in the UHMW multimer quantitation parameter to between 107% and 122% that of control plasma ( Figures 1A, 3) . The highest increase in the COVID-19 samples approached that of the control with autoimmune TTP (126%). The methodology for quantitation of UHMW multimers from illustrative case B26 is also shown in Figure 4 . The presence of UHMW VWF multimers did not correlate with ADAMTS13 levels ( Figure 5A and 5B respectively.

In order to investigate the effect of restoring the low ADAMTS13 levels on VWF in the patient samples, we incubated 10 plasma samples from COVID-19 patients with different concentrations of rADAMTS13 and monitored VWF activity and multimer composition over time. In plasma from illustrative patient S12 (VWF:Ag 4.36 IU/mL, Table 2 ). This decrease in VWF activity was accompanied by a statistically significant increase (P<0.001; t-value -7.04) in VWF dimers measured by densitometry ( Table 2 ).

The effect of supplementing ADAMTS13 to higher levels was tested using plasma from patient B1 in which there was a greater VWF/ADAMTS13 mismatch (VWF:Ag 5.76 IU/mL; ADAMTS13 0.43 IU/mL; ratio 13.4). Incubation with 10 IU/mL rADAMTS13 resulted in a progressive reduction in VWF activity over time achieving J o u r n a l P r e -p r o o f more than a 60% reduction at 5 hours ( Figure 7A ) and disappearance of all the abnormal UHMW VWF multimers visualised using the semi-automated electrophoresis method ( Figure 7B ). The effect of 1 IU/mL rADAMTS13, was less pronounced although this was still sufficient to cause a reduction in VWF activity and a visible depletion of UHMW VWF within 2 hours. Disappearance of UHMW VWF was accompanied by marked increase in low molecular weight multimers and dimers ( Figure 7C ). These findings were also present with the home cast gels which showed that the elevated UHMW multimer quantitation parameter of 124% reduced by 16% after 5 hours of incubation with 1 IU/mL rADAMTS13 and by 36% with 10 IU/mL rADAMTS13, to a level lower than that observed in control plasma (88%). Exposure of VWF to rADAMTS13 resulted in the appearance of higher quantities of lower sized multimers with an increase in stainable satellite bands indicative of proteolytic cleavage of VWF.

In this exploratory investigation, we evaluated the VWF/ADAMTS13 axis in adults admitted to two hospitals for mechanical ventilation due to severe COVID-19. The liberal inclusion criteria enabled enrolment of a cross-sectional cohort of patients early in the course of severe COVID-19 and also those with established disease requiring prolonged ventilation. The cohort contained a preponderance of older males with multiple comorbidities and was over-represented with patients from black and ethnic minority groups and with non-O blood groups. These characteristics, and the frequency of adverse outcomes mirrors previously reported severe COVID-19 cohorts [30, 31] .

The striking finding in this clinically heterogeneous cohort was that all patients had substantially elevated circulating VWF levels that in some cases were up to ten-fold higher than normal. We believe that the extent to which VWF is dysregulated in this cohort is greater than in any previously reported inflammatory illness and reproduces previous observations in severe COVID-19 patients [2, 10, 12, 15] . We also show that most patients had decreased circulating levels of ADAMTS13 protein and ADAMTS13 proteolytic activity in most cases to between 30% to 70% of normal levels and resulting in a substantially abnormal VWF/ADAMTS13 ratio. These data confirm other recent observations from COVID-19 case series of reduced ADAMTS13 activity [10, [13] [14] [15] or markedly increased VWF/ADAMTS13 ratio [12, 32, 33] . Although in a further small case series in which comprehensive haemostasis testing was performed longitudinally in COVID-19 patients for the duration of hospital admission, reduced ADAMTS13 was an inconsistent finding [34] . It is noteworthy that low ADAMTS13 plasma levels predicted mortality in COVID-19 patients in three independent studies [16, 35, 36] .

One possible explanation for reduced ADMATS13 levels is sequestration of ADAMTS13 by high levels of circulating high molecular weight VWF multimers through a low affinity interaction that does not result in multimer cleavage [37] . Low ADAMTS13 levels may also be a consequence of the cytokine storm that accompanies severe COVID-19 because normal ADAMTS13 synthesis from cultured human cell lines is inhibited by inflammatory cytokines such as IFN-γ, IL-4 and TNFα [38] . Inflammatory cytokines also inhibit ADAMTS13-mediated cleavage of UHMW VWF multimers [39] .

We also show that in all of the COVID-19 patients these reciprocal changes in the plasma levels of VWF and ADAMTS13 were accompanied by abnormal circulating UHMW VWF multimers that are completely absent in healthy controls. Circulating UHMW VWF multimers have been observed previously with trauma [40] , sepsisassociated disseminated intravascular coagulation [41] , severe malaria [42] and after endotoxin infusion in healthy volunteers [43] most likely arise because of an excess of the VWF substrate compared to ADAMTS13 resulting in incomplete VWF cleavage. Although approaching half of our patients had presumptive evidence of bacterial infection, particularly localised to intravascular lines, none displayed DIC or any other previously recognised cause for VWF/ADAMTS13 mismatch. The extent of mismatch was also much greater than reported in other inflammatory settings, resulting in dramatically higher levels of potentially thrombogenic UHMW VWF multimers These observations directly support the recently proposed hypothesis that coagulopathy following SARS-CoV-2 infection is driven by a potent inflammatory endotheliopathy resulting in disordered regulation of multiple components of hemostasis, including the coagulation and fibrinolysis pathways as well as the platelet-endothelium interaction [44, 45] . Our findings specifically implicate abnormal release of granular stores of VWF and dysregulated proteolysis of VWF in the pathogenesis of thrombosis as has been proposed by others [3, 39, 46] . However, to our knowledge our investigation is the first to directly visualise that a consequence of VWF/ADAMTS13 mismatch is the presence of UHMW VWF multimers in COVID-19 plasma samples. The UHMW VWF multimers levels in some COVID19 patients were approaching those of the acute TTP control. However, even though micro-vascular J o u r n a l P r e -p r o o f occlusion is a feature of both COVID-19 and acute TTP, the COVID19 coagulopathy is distinct because of the absence of TTP features such as severe thrombocytopenia, circulating red cell schistocytes and severe reduction in ADAMTS13 level. Therefore, our findings fit best with a model in which VWF dysregulation is an important component of COVID-19 coagulopathy but that dysfunction of other haemostatic pathways are contributory [44] .

Our findings are potentially significant for the management of patients with COVID-19 because the VWF-ADAMTS13 axis is a therapeutically accessible target. We show early evidence of the potential utility of ADAMTS13 replacement by showing that incubation of patient samples with rADAMTS13 resulted in a time and concentration dependent reduction in VWF activity, even in the sample with the most severe mismatch between VWF and ADAMTS13. We showed further that this correction of abnormally high VWF activity was accompanied by the disappearance of UHMW VWF multimers and time-dependent increase in lower molecular weight multimers with more intense satellite bands indicating ex vivo proteolysis. This pharmacodynamic effect of ADAMTS13 replacement mirrors that observed in other coagulopathies in which rADAMTS13 has been evaluated in early phase clinical trials including in patients with VWF/ADAMTS13 mismatch because of severe congenital TTP [28] and in plasma samples from patients with autoimmune TTP [47] .

rADAMTS13 also results in dissolution of thrombus in flow chamber models [48] and in a small animal model [49] of VWF/ADAMTS13 mismatch. In our study, ex vivo proteolytic activity in the COVID-19 plasma samples was even observed after correction of ADAMTS13 levels to 1.0 to 1.5 IU/mL, which was in the range achieved in the phase 1 congenital TTP study following infusion of 40 IU/Kg rADAMTS13 J o u r n a l P r e -p r o o f which was well tolerated and was not associated with significant adverse events [28] .

However, it is also noteworthy that the ADAMTS13 activity required to cleave abnormal UHMW VWF multimers in static models may be lower than in conditions of flow [50] . Therefore, caution should be used in extrapolating the effective rADAMTS13 concentrations observed in our study to the clinical setting. We also highlight a potential clinical caution of bleeding associated with the small reduction in high molecular weight VWF multimers as well as the UHMW forms observed in our ex vivo experiments.

Although anticoagulation was associated with lower mortality among hospitalized COVID-19 patients [51] it is significant that anti-thrombotic drugs such as heparin that target the coagulation pathway may be less effective in preventing thrombosis in severe COIVID-19 than in other inflammatory diseases [52] . The dramatic abnormalities in the VWF-ADAMTS13 axis demonstrated in our investigation provide a potential explanation for this. Our demonstration that ADAMTS13 replacement restores VWF homeostasis in COVID-19 plasma samples suggests that a purified rADAMTS13 should be considered as a potential therapeutic intervention for COVID-19 coagulopathy alongside other anti-thrombotic therapies. 

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Endothelial cell infection and endotheliitis in COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

CoroNerve Study, Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

ADAMTS-13 and von Willebrand factor: a dynamic duo

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions

Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features

Role of von Willebrand Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time to Rethink

Endothelial cells orchestrate COVID-19 coagulopathy

ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation

A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19

Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2

Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients

Acute respiratory distress syndrome: the Berlin Definition

A serological assay to detect SARS-CoV-2 seroconversion in humans

Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity

VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)

Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Subcommittee on Disseminated Intravascular, A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH

Semple, I.C. investigators, Features of 20 133 UK patients in hospital with covid-19 using the

ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

COVID-19 is associated with relative ADAMTS13 deficiency and VWF multimer formation resembling TTP

Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study

Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients

Evidence for secondary thrombotic microangiopathy in COVID-19, medRxiv

Multistep binding of ADAMTS-13 to von Willebrand factor

Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in ADAMTS13 activity

ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock

Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition

Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease

Willebrand factor during acute systemic inflammation

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

COVID19 coagulopathy in Caucasian patients

Severe COVID-19 infection associated with endothelial activation

Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura

ADAMTS13 exerts a thrombolytic effect in microcirculation

Variations among normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand factor under flow

Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests